Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

PDGFR α-β inhibitor

DRUG CLASS:

PDGFR α-β inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

FGFR1 overexpression + HR positive	HER2 Negative Breast Cancer	FGFR1 overexpression + HR positive	HER2 Negative Breast Cancer	E 3810 Sensitive: C3 – Early Trials E 3810 Sensitive : C3	E 3810 Sensitive: C3 – Early Trials E 3810 Sensitive : C3
FGF amplification	Breast Cancer	FGF amplification	Breast Cancer	E 3810 Sensitive: C3 – Early Trials E 3810 Sensitive : C3	E 3810 Sensitive: C3 – Early Trials E 3810 Sensitive : C3
FGFR1 amplification + HR positive	HER2 Negative Breast Cancer	FGFR1 amplification + HR positive	HER2 Negative Breast Cancer	E 3810 Sensitive: C3 – Early Trials E 3810 Sensitive : C3	E 3810 Sensitive: C3 – Early Trials E 3810 Sensitive : C3
PALB2 mutation	Endometrial Cancer	PALB2 mutation	Endometrial Cancer	rucaparib + E 3810 Sensitive: C4 – Case Studies rucaparib + E 3810 Sensitive : C4	rucaparib + E 3810 Sensitive: C4 – Case Studies rucaparib + E 3810 Sensitive : C4